Beta thalassemia major (β-TM) is an autosomal recessive disorder caused by the inheritance of null alleles (usually 0 point mutations) in both HBB genes (chromosome 11p15.5). Typically, β-TM patients are asymptomatic at birth but, due to the decrease of the expression of -globin genes, during the first six months of life they become transfusion dependent.
Late β-TM presentation is an extremely rare condition. To our knowledge only one case has been previously reported by Chang JG et al 1 who described a patient with thalassemia major presenting at 28 years of age. β-TM late presentation was secondary to the loss of heterozigosity (LOH) due to acquired paternal uniparental disomy (UPD) involving 11p15.5 chromosomal region. LOH can also be a consequence of acquired large deletions in the same region, and some cases have been described associated with late presentation of β-thalassemia intermedia 2, 3 . We describe a case of acquired β-TM in a young woman diagnosed in childhood as a β-thalassemia carrier. At the age of 7 years, according to the clinical report, her hematological parameters were: Hb 10.5 g/dL; MCV 60 fL; MCH 20pg, and Hb A2=5,2%, compatible with β-thalassemia trait. At the age of 15 years she started to complain with fatigue and her hemoglobin level was progressively decreasing to values around 9-10 g/dl. By the age of 17 years she starts having fatigue, that limited her daily routine, her hemoglobin was 8-9 g/dL, needing sporadic transfusions. Her spleen and liver became slightly enlarged (by ultrasound). She was started on hydroxyurea, which was discontinued due to thrombocytopenia. The transfusion intervals became shorter and at 21 years of age she started a regular transfusion program, every 3 to 4 weeks. Due to severe hepatic iron overload, deferasirox (25 mg/Kg/day) was introduced.
Her father and sister are β-thalassemia carriers and her mother has normal hematological parameters.
After obtaining informed consent from the patient and the family, total genomic DNA was isolated from white blood cells (WBC). From the patient, DNA was also extracted from oral mucosa epithelial cells and skin fibroblasts. HBB gene direct sequencing revealed heterozygosity for the HBB [c.48G>A] mutation [β 0 CD15 (TGG-TGA); p.W16X] in her father and sister. No mutations were found in the mother's HBB genes.
Sequencing of patient's DNA extracted from WBC and oral mucosa showed a strong peak due to the HBB 48G>A mutated allele and a very weak signal corresponding to the normal allele. On DNA extracted from skin fibroblasts the patient is heterozygous for the HBB [c.48G>A] mutation, with a sequencing pattern similar to the one observed in father and sister (Figure 1 ). These observations strongly suggest the occurrence of an acquired mutation affecting only the blood cell lineage. The fact that the homozygous pattern can be seen also in the DNA extracted from the oral mucosal was probably due to the contamination of leukocytes in the saliva 4 . In order to define the chromosomal aberration leading to homozygosity of the HBB gene mutation we performed high-resolution genotyping and loss of heterozygosity mapping on the DNA sample from the patient using Affymetrix Genome-Wide Human SNP 6.0 arrays. We identified a 8.8Mb long acquired uniparental disomy of chromosome 11p, covering the position of the HBB gene (Figure 2) . The patient has 2 copies of chromosome 11, however the 11p region shows an acquired loss of heterozygosity. Based on the allelic difference results obtained from the array we estimate that the clone carrying the UPD and the mutation represents >80% of cells in whole blood. We did not detect any other copy number changes or losses of heterozygosity in the patient's genome using the microarray.
HBB gene dosage analysis was confirmed by multiplex ligation-dependent probe amplification (MLPA) using the HBB SALSA MLPA kit (MRC-Holland, Amsterdam, the Netherlands). Fragment analysis was performed on the ABI Prism 3130. Data were analysed using Coffalyser MLPA software. All peaks observed in WBC DNA were within the normal range.
We further performed the methylation analysis of H19 differentially methylated region (DMR) and KvDMR domains in patient's DNA extracted from WBC and from skin fibroblasts. In a normal subject H19DMR is hypermethylated in the paternal allele and KvDMR is hypermethylated in the maternal allele 5 . Methylation status analysis of H19DMR and KvDMR showed hypermethylation of the H19DMR and no methylation of the KvDMR in patient's WBC DNA, and 50 % methylation of both domains in the patient's skin fibroblasts DNA (data not shown).
These results prove the hypothesis that the acquired β-TM in this patient is due to paternal uniparental isodisomy and mosaicism of chromosomal region 11p14.3-11p15.5.
UPD, first reported and recently reviewed by Engel 6, 7 , occurs frequently in various tumour tissues 8 . Beldjord C et al 1 described a child with Wiedemann-Beckwith syndrome and β-TM due to uniparental isodisomy of paternal origin 9 . It has recently been shown that the acquired UPD can amplify germline variants to homozygosity affecting the disease course of haematological malignancies 10 . LOH, with a homozyogous paternal hypermethylated H19MDR, would correlate with the activation and overexpression of the adjacent and reciprocally imprinted Insulin-like growth factor 2 (IGF2) 11 , which could play a role in cellular proliferation, favouring its growth over the clone with the HBB [c.48G>A] mutation in heterozygosy. This clone preferential proliferation would have given rise to the major hemopoietic cell clone in bone marrow, resulting in the β-TM phenotype. 
